2024
Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection
Resio B, Tan K, Skovgard M, Dycoco J, Adusumilli P, Bains M, Bott M, Downey R, Gray K, Huang J, Molena D, Park B, Rusch V, Sihag S, Rocco G, Jones D, Isbell J. Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection. The Annals Of Thoracic Surgery 2024, 119: 308-315. PMID: 39299477, DOI: 10.1016/j.athoracsur.2024.09.009.Peer-Reviewed Original ResearchConceptsClinical stage IClinical stage III patientsStage III patientsStage IIII patientsLung resectionHilar lymph node stationsRate of nodal upstagingSystemic therapy administrationProspective institutional databaseLung cancer resectionLymph node stationsIn-hospital complicationsLymph node samplingLung cancer patientsDistant recurrenceNodal upstagingOncological outcomesPulmonary resectionOverall survivalCancer resectionDecrease recurrenceClinical stageII patientsImproved survivalArtificial Intelligence Helps Pathologists Increase Diagnostic Accuracy and Efficiency in the Detection of Breast Cancer Lymph Node Metastases
Retamero J, Gulturk E, Bozkurt A, Liu S, Gorgan M, Moral L, Horton M, Parke A, Malfroid K, Sue J, Rothrock B, Oakley G, DeMuth G, Millar E, Fuchs T, Klimstra D. Artificial Intelligence Helps Pathologists Increase Diagnostic Accuracy and Efficiency in the Detection of Breast Cancer Lymph Node Metastases. The American Journal Of Surgical Pathology 2024, 48: 846-854. PMID: 38809272, PMCID: PMC11191045, DOI: 10.1097/pas.0000000000002248.Peer-Reviewed Original ResearchConceptsLymph node metastasisNode metastasisDetection of lymph node metastasesBreast cancer lymph node metastasisMetastasis detection rateWhole slide imagesBreast cancer stageArtificial intelligenceIncrease diagnostic accuracyReading pathologistsCancer stageDiagnostic accuracyMetastasisCancer metastasisAverage reading timeBreastPathologistsDetection rateAI algorithmsImmune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer
Michikawa C, Gleber-Netto F, Pickering C, Rao X, Wang J, Sikora A, Myers J, Frederick M. Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer. Oral Oncology 2024, 153: 106729. PMID: 38663156, DOI: 10.1016/j.oraloncology.2024.106729.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Squamous CellExtranodal ExtensionFemaleHumansLymphatic MetastasisMaleMiddle AgedMouth NeoplasmsPrognosisConceptsOral cavity squamous cell carcinomaAssociated with clinical outcomesExtranodal extensionLymph node metastasisImmune infiltrationImmune infiltration statusOverall survivalPrimary tumorNode metastasisOral cancerInfiltration statusClinical outcomes of OSCC patientsExtension of lymph node metastasesAssociated with clinical outcomes of patientsAssociated with OS rateLocally advanced oral cancerClinical outcomes of patientsOutcome of OSCC patientsAssociated with poor overall survivalImmune infiltration of tumorsLow immune infiltrationNode negative tumorsAdvanced oral cancerHuman papillomavirus-negativeInfiltration of tumors
2023
Perfluorobutane-enhanced US Helps Differentiate Benign Lymph Nodes from Papillary Thyroid Cancer Metastases.
Gunabushanam G. Perfluorobutane-enhanced US Helps Differentiate Benign Lymph Nodes from Papillary Thyroid Cancer Metastases. Radiology 2023, 307: e230581. PMID: 37014247, DOI: 10.1148/radiol.230581.Commentaries, Editorials and LettersAssociation Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer: Potential for Stage Classification Reform
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Udelsman B, Nemeth A, Boffa D. Association Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer: Potential for Stage Classification Reform. Annals Of Surgical Oncology 2023, 30: 4180-4191. PMID: 36869917, DOI: 10.1245/s10434-023-13287-9.Peer-Reviewed Original ResearchMeSH KeywordsHumansLymphatic MetastasisNeoplasm StagingPrognosisProportional Hazards ModelsRetrospective StudiesStomach NeoplasmsConceptsStage IV gastric cancerNonregional lymph nodesMultivariable Cox modelLymph nodesGastric cancerMetastatic patternCox modelStage IV gastric cancer patientsBetter median survivalNational Cancer DatabaseRetrospective cohort studyStage IV patientsKaplan-Meier curvesGastric cancer patientsPropensity score-matched sampleSingle organYears of ageDistant diseaseCohort studyIV patientsMedian survivalMetastatic diseaseMost patientsBetter prognosisSystemic organs
2022
AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers
Lerner G, Tang H, Singh K, Golestani R, St Claire S, Humphrey P, Lannin D, Janostiak R, Harigopal M. AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers. Clinical Breast Cancer 2022, 23: 199-210. PMID: 36577560, DOI: 10.1016/j.clbc.2022.11.012.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaTriple-negative breast cancerHigh histologic gradeApocrine differentiationAMACR expressionEstrogen receptorApocrine DCISER-/PRHistologic gradeProgesterone receptorApocrine featuresBreast cancerHuman epidermal growth factor 2 (HER2) statusLack of ERDistant metastasis-free survivalDiagnostic markerInitial N stageLack estrogen receptorApocrine breast cancerLymph node metastasisNegative breast cancerAndrogen receptor mRNACoA racemase expressionBenign breast tissueBreast cancer cohortIncreased Expression of LEF1 and β-Catenin in Invasive Micropapillary Carcinoma of the Breast is Associated With Lymphovascular Invasion and Lymph Node Metastasis
Dolezal D, Zhang X, Harigopal M. Increased Expression of LEF1 and β-Catenin in Invasive Micropapillary Carcinoma of the Breast is Associated With Lymphovascular Invasion and Lymph Node Metastasis. Applied Immunohistochemistry & Molecular Morphology 2022, 30: 557-565. PMID: 35960138, DOI: 10.1097/pai.0000000000001052.Peer-Reviewed Original ResearchMeSH Keywordsbeta CateninBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, PapillaryFemaleHumansLymphatic MetastasisLymphoid Enhancer-Binding Factor 1ConceptsInvasive micropapillary breast carcinomaLymph node metastasisLymphoid enhancer-binding factor 1Lymphovascular invasionNode metastasisNodal metastasisPrimary tumorΒ-cateninBreast tumorsRare breast cancer subtypeSmall tumor cell clustersLEF1 expressionMicropapillary breast carcinomaAggressive breast tumorsBasal-like carcinomasInvasive micropapillary carcinomaΒ-catenin expression levelsBreast cancer subtypesΒ-catenin expressionTumor cell clustersEnhancer-binding factor 1Disease relapseMicropapillary carcinomaBreast carcinomaHigh incidenceImaging Cancer in Pregnancy
Jha P, Pōder L, Glanc P, Patel-Lippmann K, McGettigan M, Moshiri M, Nougaret S, Revzin MV, Javitt MC. Imaging Cancer in Pregnancy. RadioGraphics 2022, 42: 1494-1513. PMID: 35839139, DOI: 10.1148/rg.220005.Peer-Reviewed Original ResearchConceptsContrast materialCancer-related symptomsMultidisciplinary team approachAdvanced maternal ageIntravenous contrast materialGadolinium-based contrast materialSafety of motherWhole-body MRIRadiation dose concernsDiffusion-weighted sequencesGestational ageGestational changesMetastatic sitesYear postpartumDisease stageTreatment optionsMaternal ageClinical managementImaging triageOnline supplemental materialSide effectsAccurate diagnosisTeam approachPregnancyCancer-specific imagingSentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma
Cheraghlou S, Ugwu N, Girardi M. Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma. JAMA Dermatology 2022, 158: 51-58. PMID: 34878492, PMCID: PMC8655663, DOI: 10.1001/jamadermatol.2021.4812.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesFemaleHumansLymphatic MetastasisMelanomaMiddle AgedPrognosisRetrospective StudiesSentinel Lymph Node BiopsySkin NeoplasmsConceptsAcral lentiginous melanomaNational Cancer DatabaseClinical stage IBSLN positivityStage IBSentinel lymphCutaneous melanomaPositivity rateMalignant melanomaHigh riskSentinel lymph node statusAJCC Cancer Staging ManualClinical stage IRetrospective cohort studySignificant prognostic factorsLymph node statusCancer Staging ManualMultivariable logistic regressionHigher positivity rateAJCC clinical stageCohort studySLN statusPrognostic factorsSuch patientsStaging Manual
2021
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal Of Medicine 2021, 385: 2336-2347. PMID: 34914339, PMCID: PMC9096864, DOI: 10.1056/nejmoa2108873.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleGene Expression ProfilingHumansLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalPostmenopausePremenopauseProspective StudiesReceptor, ErbB-2Receptors, SteroidReverse Transcriptase Polymerase Chain ReactionConceptsInvasive disease-free survivalDistant relapse-free survivalDisease-free survivalRelapse-free survivalChemotherapy benefitRecurrence scoreBreast cancerChemoendocrine therapyAdjuvant chemotherapyPostmenopausal womenPremenopausal womenLymph nodesAxillary lymph node-negative breast cancerLymph node-negative breast cancerPositive axillary lymph nodesHER2-negative breast cancerNode-positive breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Positive lymph node diseasePositive lymph nodesSecondary end pointsAxillary lymph nodesLymph node diseaseGrowth factor receptor 2Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.
Laws A, Garrido-Castro A, Poorvu P, Winer E, Mittendorf E, King T. Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer. Oncology 2021, 35: 77-84. PMID: 33577165, DOI: 10.46883/onc.2021.3502.0077.Peer-Reviewed Original ResearchConceptsRecurrence scorePositive nodesClinical trialsBreast cancerHER2-negative breast cancerNode-positive breast cancerLarge population-based registryNode-positive populationAdjuvant chemotherapy useChemotherapy-treated patientsClinical practice guidelinesCurrent practice patternsPopulation-based registryMultiple clinical trialsPotential predictive valueADAPT trialAdjuvant chemotherapyChemotherapy useEndocrine therapyPostmenopausal patientsChemotherapy benefitExcellent outcomesPractice patternsPractice guidelinesRetrospective analysisExamination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study
Pathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, Kunz PL, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer 2021, 154: 186-194. PMID: 33551175, PMCID: PMC8026717, DOI: 10.1016/j.lungcan.2021.01.017.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoid TumorHumansLungLung NeoplasmsLymph NodesLymphatic MetastasisNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesConceptsLung neuroendocrine tumorsLymph nodesNeuroendocrine tumorsLung carcinoidsSSTR imagingLN metastasisAtypical carcinoidExact testSingle-institution retrospective cohort studyLymph node-positive diseaseAssociation of lymphPositive lymph nodesRetrospective cohort studyLymph node diseaseLymph node involvementNode-positive diseaseLymph node metastasisMultivariable logistic regressionFisher's exact testPre-operative workupN2 diseaseAdjuvant therapyLN involvementN1 diseaseNode involvement
2020
Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination
Sundar R, Liu D, Hutchins G, Slaney H, Silva A, Oosting J, Hayden J, Hewitt L, Ng C, Mangalvedhekar A, Ng S, Tan I, Tan P, Grabsch H. Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Gut 2020, 70: 1823-1832. PMID: 33229445, PMCID: PMC8458060, DOI: 10.1136/gutjnl-2020-320805.Peer-Reviewed Original ResearchConceptsPrimary gastric cancerLymph node metastasisPrimary tumorGastric cancerIntratumour heterogeneityNode metastasisMatched lymph node metastasesRegional lymph node metastasisMultiplex ligation-dependent probe amplificationLigation-dependent probe amplificationPatient-matchedProgressive genomic changesDNA copy number profilesEndoscopic mucosal biopsiesCopy number profilesTherapeutically relevant genesLocoregional metastasesTumor disseminationResected samplesTargeted therapyHistomorphological phenotypesProbe amplificationBiomarker testingClinical trialsNanoString resultsPathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy
Ghali F, Daly W, Hansen M, Hayn M, Sammon J, Beaule L, Sarkar R, Murphy J, Kader A, Derweesh I, Rose B, Ryan S. Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy. Urologic Oncology Seminars And Original Investigations 2020, 39: 130.e1-130.e7. PMID: 33121914, DOI: 10.1016/j.urolonc.2020.08.035.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansLymphatic MetastasisMaleMiddle AgedNeoplasm StagingProstatectomyProstatic NeoplasmsRetrospective StudiesSurvival RateConceptsNodal statusRadical prostatectomyOverall survivalDiscordant stagingDiscordant statusSimilar OSLymph nodesClinical positive lymph nodesNational Cancer Data BaseClinical nodal stagingDefinitive locoregional therapyPathologic nodal statusUnderwent radical prostatectomyPositive lymph nodesPositive nodal statusLow Gleason scoreNegative node statusDifficult clinical scenariosKaplan-Meier estimationCharlson indexClinical nodalCM1 diseaseCT1-3Noncurative therapyPathologic nodalPrimary Treatment Selection for Clinically Node‐Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node‐Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.Peer-Reviewed Original ResearchConceptsNode-negative Merkel cell carcinomaLymph node evaluationImproved overall survivalPrimary tumor excisionMerkel cell carcinomaCase volumeOverall survivalSurgical managementCell carcinomaTumor excisionTreatment selectionNode evaluationCox proportional hazards regressionGuideline-recommended carePrimary treatment selectionNational Cancer DatabaseNode-negative diseasePercentage of patientsRetrospective cohort analysisInitial surgical managementKaplan-Meier analysisWide local excisionProportional hazards regressionRates of receiptInitial managementOutcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium
Shaikh F, Stark D, Fonseca A, Dang H, Xia C, Krailo M, Pashankar F, Rodriguez‐Galindo C, Olson TA, Nicholson JC, Murray MJ, Amatruda JF, Billmire D, Stoneham S, Frazier AL. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium. Cancer 2020, 127: 193-202. PMID: 33079404, DOI: 10.1002/cncr.33273.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolHumansInfantInfant, NewbornLymphatic MetastasisMaleMediastinal NeoplasmsNeoplasms, Germ Cell and EmbryonalProgression-Free SurvivalRetroperitoneal NeoplasmsRetrospective StudiesTesticular NeoplasmsYoung AdultConceptsMetastatic germ cell tumorsEvent-free survivalGerm cell tumorsCell tumorsRisk groupsYoung adultsAge groupsMale patientsAdolescent patientsAdolescent malesCox proportional hazards analysisMalignant germ cell tumorsIndividual patient databasePlatinum-based chemotherapyProportional hazards analysisYoung adult patientsClinical trial organizationsAdolescent age groupPediatric cooperative groupsTreatment of adolescentsDifferent age groupsAdult patientsClinical characteristicsEFS rateInclusion criteriaOsimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer. New England Journal Of Medicine 2020, 383: 1711-1723. PMID: 32955177, DOI: 10.1056/nejmoa2027071.Peer-Reviewed Original ResearchMeSH KeywordsAcrylamidesAdultAgedAged, 80 and overAniline CompoundsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantDisease-Free SurvivalDouble-Blind MethodErbB ReceptorsFemaleHumansLung NeoplasmsLymphatic MetastasisMaleMiddle AgedMutationNeoplasm Recurrence, LocalNeoplasm StagingPneumonectomyProtein Kinase InhibitorsConceptsDisease-free survivalMutation-positive NSCLCIIIA diseasePlacebo groupOsimertinib groupStage IBLung cancerUntreated epidermal growth factor receptorNon-small cell lung cancerOverall populationStage IIEnd pointCentral nervous system diseaseSafety of osimertinibPrimary end pointSecondary end pointsPhase 3 trialOverall survival dataCell lung cancerNew safety concernsNervous system diseasesEpidermal growth factor receptorGrowth factor receptorAdjuvant therapyOverall survivalMeta-analysis of the clinicopathological significance of miRNA-145 in breast cancer
Lv P, Zhang Z, Hou L, Zhang Y, Lu L, Wang C, Shi F. Meta-analysis of the clinicopathological significance of miRNA-145 in breast cancer. Bioscience Reports 2020, 40: bsr20193974. PMID: 32869851, PMCID: PMC7502658, DOI: 10.1042/bsr20193974.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreastBreast NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMicroRNAsTumor BurdenConceptsMiR-145 expressionBreast cancer patientsBreast cancerStandardized mean differenceBreast cancer tissuesAdjacent normal tissuesMiR-145Cancer patientsTumor suppressor miRNACancer tissuesLow expressionNormal tissuesLymph node metastasisUnfavorable prognostic factorLargest tumor diameterSuppressor miRNALower miR-145Normal breast tissueWeb of ScienceNode metastasisPrognostic factorsHealthy womenTumor diameterClinicopathological significanceEligible studiesEpithelium Involving Bilateral Axillary Lymph Nodes: Metastasis, Misplaced, or Mullerian!
Singh K, Sardana R, Quddus MR, Harigopal M. Epithelium Involving Bilateral Axillary Lymph Nodes: Metastasis, Misplaced, or Mullerian! International Journal Of Surgical Pathology 2020, 29: 284-288. PMID: 32924678, DOI: 10.1177/1066896920958121.Peer-Reviewed Original ResearchConceptsSentinel lymph nodesBilateral axillary lymph nodesAxillary sentinel lymph nodesAxillary lymph nodesFrozen section examinationLymph nodesDifferential diagnosisEpithelial depositsSection examinationBreast cancer stagingNodal depositsCancer stagingHistological evaluationEpithelial restsEndosalpingiosisFirst caseDiagnosisEpitheliumExaminationMetastasisStagingMullerianInvasive Staging Procedures Do Not Prevent Nodal Metastases From Being Missed in Stage I Lung Cancer
Resio BJ, Canavan M, Mase V, Dhanasopon AP, Blasberg JD, Boffa DJ. Invasive Staging Procedures Do Not Prevent Nodal Metastases From Being Missed in Stage I Lung Cancer. The Annals Of Thoracic Surgery 2020, 110: 390-397. PMID: 32283084, DOI: 10.1016/j.athoracsur.2020.03.026.Peer-Reviewed Original ResearchConceptsStage I lung cancerI lung cancerMissed nodal metastasisClinical stage I lung cancerNodal metastasisLung cancerPositron emission tomographyStaging evaluationCancer patientsEndobronchial ultrasoundInvasive nodalClinical stage I patientsEarly-stage lung cancer patientsOccult lymph node metastasisEmission tomographyThoracic Surgeons General Thoracic Surgery DatabaseInvasive staging proceduresClinical stage IStage I patientsTreatment-naive patientsGeneral Thoracic Surgery DatabaseLow-risk cohortOccult nodal metastasisLymph node metastasisLung cancer patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply